SLC6A6

Across TCGA pan-cancer cohorts, SLC6A6 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SLC6A6’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SLC6A6 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SLC6A6 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where SLC6A6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC6A6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−1.286	<.001	12	view →
LSCC	Male	III,IV	+1.041	<.001	8	view →
LUAD	Female	III,IV	+0.550	.012	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

SLC6A6–CCRCC

Open the CCRCC breakdown →